+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Regenerative Medicines Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 To 2030

  • PDF Icon

    Report

  • 110 Pages
  • September 2022
  • Region: Global
  • Acute Market Reports
  • ID: 5656325
The global regenerative medicine market is expected to reach $40 billion growing at a CAGR of 18% during the forecast period 2022 to 2030. The death of organs and tissues as a result of disease or organ damage serves as a driving force behind the research and development of new medicines with the potential to regenerate tissues and lessen the need for transplantation. The field of regenerative medicine is an example of an interdisciplinary field that makes use of engineering and biological science ideas to stimulate the regeneration of organs and tissues that have been injured or damaged. The increasing prevalence of genetic and chronic illnesses is one of the primary factors that is majorly driving the growth of the market for regenerative medicine. Other factors, such as major efforts being made in medical research and development and improvements being made to healthcare infrastructure, are likely to fuel the expansion of the market. In many developed and emerging regions, the utilization of regenerative medicine requires authorization from the relevant governing bodies. In order to be marketed and sold, products related to regenerative medicine must first obtain a license or approval from the Food and Drug Administration (FDA). Therefore, the most significant obstacle to the expansion of the industry is the severe rules imposed by the government.

Increasing Geriatric Population Remains as the Key Driver

The number of people who are elderly or senior citizens is growing at a rapid rate. The World Health Organization (WHO) estimates that by the year 2050, the global population of adults aged 65 and older would have increased by around 1.5 billion. It is anticipated that the number will climb in developing nations such as China, Japan, India, and South Korea. There are a variety of health problems that are more prevalent in the elderly population, including cancer, diabetes, high blood pressure, and elevated blood sugar levels. They have a responsibility to use increased caution with regard to their health. As a direct consequence of this, people have to take their medication at predetermined intervals. The expansion of the market is also being driven by the rising number of elderly people in the world, who are more likely to experience cardiovascular and oncological issues. As a consequence of this, the growing acceptability of organ transplantation is also contributing to the expansion of the market for regenerative medicine. As a consequence of this, during the period covered by the forecast, the expanding population of elderly people would act as a primary driver of growth in the regenerative medicine market.

Expensive Nature of Treatment Hindering the Market Growth

The development of gene and cell treatments has been an enormous step forward in the treatment of individuals who are afflicted with life-threatening conditions and serious conditions. These treatments are contributing to a revolution that is taking place in the manner in which diseases are treated and cured. The demand for these therapies is significantly less than what was anticipated, despite the fact that these medicines are incredibly beneficial in terms of saving lives. This is because of the high prices of these therapies, which are hampering the expansion of the market.

Cancer Immunotherapy Promising Significant Opportunities During the Forecast Period

The development of cancer is a multi-step process that often starts with a pre cancerous lesion and ultimately results in a malignant tumor. Cancer is produced by the change of normal cells into tumor cells during the course of this process. These alterations are brought about by the interaction of many genetic elements within a person. The World Health Organization estimates that cancer will be the top cause of mortality worldwide, accounting for around 10 million fatalities every year by the end of 2020. A proper cancer diagnosis is absolutely necessary in order to ensure that a patient receives therapy that is both successful and suited to their particular form of the disease. Cancer is typically treated with a combination of chemotherapy, radiation, and surgery. Because of the innate capability of hematopoietic stem cells and other more mature cells, cancer immunotherapy that makes use of regenerative medicine has the distinct benefit of being able to specifically target and eradicate disease cells. In addition to this, it makes it possible to gain a deeper understanding of cancer cells, which is essential for the creation of successful treatments. As a consequence of this, increasing consumer demand for cancer treatment products, in conjunction with the growing prevalence of the condition, will produce chances for the market's expansion.

Therapeutics Topped the Product Market, While Musculoskeletal Segment Led the Application Market

In terms of the product, the therapeutics category controlled the majority of the global market for regenerative medicine in 2021, holding the greatest market share of 57%. Due to the fact that they can be utilized for a wide number of therapeutic applications, primary cell-based therapies are now the most developed drugs that are available within the therapeutics sector. With respect to the application, it is anticipated that the musculoskeletal section will be the segment that will present the most opportunities during the period of the forecast. This is because there has been an increase in the number of cases of orthopedic disorders, the number of clinical trials, the number of stem cell research projects, and the availability of a large supply of stem cell products for the treatment of musculoskeletal issues. According to the U.S. In medical facilities run by Medicare and Medicaid, there are approximately 900,000 operations performed annually that call for bone replacement or repair. Because of the annual occurrence of almost 15 million fracture cases, the cost of providing medical care in the United States is increased by USD 60 billion.

North America to Dominating the Market Revenue

In 2021, North America had the greatest revenue share, accounting for more than 41% of total revenue. The presence of a significant number of leading market players in the United States, as well as the presence of research organizations involved in the development of novel treatments and the accessibility of modern technology, all contribute to the high number of clinical trials conducted in North America. In addition, the development of cutting-edge technology for the diagnosis and treatment of chronic disorders, the accessibility of funding from both the private sector and the public sector, and increased spending on healthcare all contribute to a larger share of the regional market for tissue engineering. It is expected that the United States will account for a considerable portion of the total revenue due to the availability of cash provided by the government as well as the high investments made by private companies. In order to put regenerative medicine and stem cell therapy at the forefront of modern medical practice, the United States Department of Health has created the program known as "2020: A New Vision." The revolutionary effect that the application of regenerative medicine in clinical settings has is of the utmost significance for the progression of technological innovation and translation.

The Asia Pacific to Emerge as the Fastest Growing Region During the Forecast Period

Asia Pacific is expected to register the highest CAGR during the forecast period of 2022 to 2030. The Asia-Pacific area is the region of the regenerative medicine industry that is increasing at the highest rate. The regulatory structure has resulted in an increase in the number of clinical tests being conducted on cell-based and regenerative treatments. As a direct consequence of this, the market for regenerative medicine in the region has expanded. Increasing medical demands, an increasing population that is becoming older, and shifting lifestyles are some of the main reasons that are having an impact on the expansion of the global market for regenerative medicine in the Asia-Pacific region. The field of tissue engineering counts Japan as one of the leading countries in the world in terms of fostering technological advancement. Developed countries like the United States often outsource their tissue engineering work to Japan since the Japanese market is so competitive. Additionally, its regulatory approach is conducive to the approval of clinical trials in a more expedient manner. The Regenerative Medicine Law has been adopted by the Ministry of Health, Labor, and Welfare (MHLW), which paves the way for the adoption of processes that have the potential to speed up the clinical development of regenerative and cell-based medicines. In addition, a rise in the incidence of clinical conditions such as cancer in Asia is anticipated to be a driving force behind the expansion of the market for tissue engineering in this region. Other factors, such as the development of 3D bioprinting and the rise of medical tourism in the region, also contribute to the expansion of the industry.

Strategic Collaborations to Enhance Market Position of the Market Players

The companies Medtronic plc, Zimmer Biomet Holdings, Inc., Allergan plc, Athersys, Inc., ACell, Inc., Organogenesis Holdings Inc., Tissue Regenix Group plc, Stryker Corporation, RTI Surgical, Inc., Integra LifeSciences Corporation, ReproCell, Inc., and Baxter International, Inc. are the key players in the market for tissue engineering. Management, manufacturing, characterization, engineering, and quality control services, together with other facilities, are provided by key vendors with specialized technologies for clinical trials and other studies involved with the development of regenerative medicines. In order to achieve a competitive advantage over their rivals, key players are entering into agreements to collaborate to enhance technical expertise and market reach. In addition to this, prominent players are currently working on the creation of novel products for tissue engineering and the upgradation of their product portfolios in order to meet the demand in the current market.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Regenerative Medicines market are as follows:
  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Regenerative Medicines market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Product

  • Cell Therapy
  • Gene Therapy
  • Tissue Engineering
  • Small Molecule & Biologic

Material

  • Synthetic material
  • Scaffold
  • Artificial vascular graft material
  • Hydrogel material
  • Biologically derived material
  • Collagen
  • Xenogeneic material
  • Genetically Engineered Material
  • Genetically Manipulated Cell
  • Three-Dimensional Polymer Technology
  • Transgenics
  • Fibroblast
  • Neural Stem Cell
  • Gene-Activated Matrices
  • Pharmaceutical
  • Biologic

Application

  • Cardiovascular
  • Oncology
  • Dermatology
  • Musculoskeletal
  • Wound healing
  • Ophthalmology
  • Neurology
  • Others

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Regenerative Medicines market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Regenerative Medicines market?
  • Which is the largest regional market for Regenerative Medicines market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Regenerative Medicines market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Regenerative Medicines market worldwide?


This product will be delivered within 2 business days.

Table of Contents

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Regenerative Medicines Market
2.2. Global Regenerative Medicines Market, By Product, 2021 (US$ Billion)
2.3. Global Regenerative Medicines Market, By Material, 2021 (US$ Billion)
2.4. Global Regenerative Medicines Market, By Application, 2021 (US$ Billion)
2.5. Global Regenerative Medicines Market, By Geography, 2021 (US$ Billion)
2.6. Impact of Covid 19
2.7. Attractive Investment Proposition by Geography, 2021
2.8. Competitive Analysis
2.8.1. Market Positioning of Key Regenerative Medicines Market Vendors
2.8.2. Strategies Adopted by Regenerative Medicines Market Vendors
2.8.3. Key Industry Strategies
2.8.4. Tier Analysis 2021 Versus 2030
2.9. Key Buying Criteria
2.10. Key Case Reports
2.11. Scenario Analysis
2.11.1. Optimistic estimates and analysis
2.11.2. Realistic estimates and analysis
2.11.3. Pessimistic estimates and analysis
2.12. Market Profiling
2.13. Sales and Marketing Plan
2.14. Top Market Conclusions
2.15. Strategic Recommendations
3. Regenerative Medicines Market: Business Outlook & Market Dynamics
3.1. Introduction
3.2. Global Regenerative Medicines Market Value, 2020 - 2030, (US$ Billion)
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.2. Market Restraints
3.3.3. Key Challenges
3.3.4. Key Opportunities
3.4. Impact Analysis of Drivers and Restraints
3.5. See-Saw Analysis
3.6. Porter’s Five Force Model
3.6.1. Supplier Power
3.6.2. Buyer Power
3.6.3. Threat Of Substitutes
3.6.4. Threat Of New Entrants
3.6.5. Competitive Rivalry
3.7. PESTEL Analysis
3.7.1. Political Landscape
3.7.2. Economic Landscape
3.7.3. Technology Landscape
3.7.4. Legal Landscape
3.7.5. Social Landscape
3.8. Heptalysis Analysis
3.9. Critical Investigation of Business Problems Through Five Whys Root Cause Analysis & Relevant Solutions
4. Regenerative Medicines Market: By Product, 2020-2030, USD (Billion)
4.1. Market Overview
4.2. Growth & Revenue Analysis: 2021 Versus 2030
4.3. Market Segmentation
4.3.1. Cell Therapy
4.3.2. Gene Therapy
4.3.3. Tissue Engineering
4.3.4. Small Molecule & Biologic
5. Regenerative Medicines Market: By Material, 2020-2030, USD (Billion)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Synthetic material
5.3.1.1. Scaffold
5.3.1.2. Artificial vascular graft material
5.3.1.3. Hydrogel material
5.3.2. Biologically derived material
5.3.2.1. Collagen
5.3.2.2. Xenogeneic material
5.3.3. Genetically Engineered Material
5.3.3.1. Genetically Manipulated Cell
5.3.3.2. Three-Dimensional Polymer Technology
5.3.3.3. Transgenics
5.3.3.4. Fibroblast
5.3.3.5. Neural Stem Cell
5.3.3.6. Gene-Activated Matrices
5.3.4. Pharmaceutical
5.3.4.1. Biologic
6. Regenerative Medicines Market: By Application, 2020-2030, USD (Billion)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2021 Versus 2030
6.3. Market Segmentation
6.3.1. Cardiovascular
6.3.2. Oncology
6.3.3. Dermatology
6.3.4. Musculoskeletal
6.3.5. Wound healing
6.3.6. Ophthalmology
6.3.7. Neurology
6.3.8. Others
7. North America Regenerative Medicines Market, 2020-2030, USD (Billion)
7.1. Market Overview
7.2. Regenerative Medicines Market: By Product, 2020-2030, USD (Billion)
7.3. Regenerative Medicines Market: By Material, 2020-2030, USD (Billion)
7.4. Regenerative Medicines Market: By Application, 2020-2030, USD (Billion)
7.5.Regenerative Medicines Market: By Region, 2020-2030, USD (Billion)
7.5.1.North America
7.5.1.1. U.S.
7.5.1.1.1. Regenerative Medicines Market: By Product, 2020-2030, USD (Billion)
7.5.1.1.2. Regenerative Medicines Market: By Material, 2020-2030, USD (Billion)
7.5.1.1.3. Regenerative Medicines Market: By Application, 2020-2030, USD (Billion)
7.5.1.2. Canada
7.5.1.2.1. Regenerative Medicines Market: By Product, 2020-2030, USD (Billion)
7.5.1.2.2. Regenerative Medicines Market: By Material, 2020-2030, USD (Billion)
7.5.1.2.3. Regenerative Medicines Market: By Application, 2020-2030, USD (Billion)
7.5.1.3. Rest of North America
7.5.1.3.1. Regenerative Medicines Market: By Product, 2020-2030, USD (Billion)
7.5.1.3.2. Regenerative Medicines Market: By Material, 2020-2030, USD (Billion)
7.5.1.3.3. Regenerative Medicines Market: By Application, 2020-2030, USD (Billion)
8. UK and European Union Regenerative Medicines Market, 2020-2030, USD (Billion)
8.1. Market Overview
8.2. Regenerative Medicines Market: By Product, 2020-2030, USD (Billion)
8.3. Regenerative Medicines Market: By Material, 2020-2030, USD (Billion)
8.4. Regenerative Medicines Market: By Application, 2020-2030, USD (Billion)
8.5.Regenerative Medicines Market: By Region, 2020-2030, USD (Billion)
8.5.1.UK and European Union
8.5.1.1. UK
8.5.1.1.1. Regenerative Medicines Market: By Product, 2020-2030, USD (Billion)
8.5.1.1.2. Regenerative Medicines Market: By Material, 2020-2030, USD (Billion)
8.5.1.1.3. Regenerative Medicines Market: By Application, 2020-2030, USD (Billion)
8.5.1.2. Germany
8.5.1.2.1. Regenerative Medicines Market: By Product, 2020-2030, USD (Billion)
8.5.1.2.2. Regenerative Medicines Market: By Material, 2020-2030, USD (Billion)
8.5.1.2.3. Regenerative Medicines Market: By Application, 2020-2030, USD (Billion)
8.5.1.3. Spain
8.5.1.3.1. Regenerative Medicines Market: By Product, 2020-2030, USD (Billion)
8.5.1.3.2. Regenerative Medicines Market: By Material, 2020-2030, USD (Billion)
8.5.1.3.3. Regenerative Medicines Market: By Application, 2020-2030, USD (Billion)
8.5.1.4. Italy
8.5.1.4.1. Regenerative Medicines Market: By Product, 2020-2030, USD (Billion)
8.5.1.4.2. Regenerative Medicines Market: By Material, 2020-2030, USD (Billion)
8.5.1.4.3. Regenerative Medicines Market: By Application, 2020-2030, USD (Billion)
8.5.1.5. France
8.5.1.5.1. Regenerative Medicines Market: By Product, 2020-2030, USD (Billion)
8.5.1.5.2. Regenerative Medicines Market: By Material, 2020-2030, USD (Billion)
8.5.1.5.3. Regenerative Medicines Market: By Application, 2020-2030, USD (Billion)
8.5.1.6. Rest of Europe
8.5.1.6.1. Regenerative Medicines Market: By Product, 2020-2030, USD (Billion)
8.5.1.6.2. Regenerative Medicines Market: By Material, 2020-2030, USD (Billion)
8.5.1.6.3. Regenerative Medicines Market: By Application, 2020-2030, USD (Billion)
9. Asia Pacific Regenerative Medicines Market, 2020-2030, USD (Billion)
9.1. Market Overview
9.2. Regenerative Medicines Market: By Product, 2020-2030, USD (Billion)
9.3. Regenerative Medicines Market: By Material, 2020-2030, USD (Billion)
9.4. Regenerative Medicines Market: By Application, 2020-2030, USD (Billion)
9.5.Regenerative Medicines Market: By Region, 2020-2030, USD (Billion)
9.5.1.Asia Pacific
9.5.1.1. China
9.5.1.1.1. Regenerative Medicines Market: By Product, 2020-2030, USD (Billion)
9.5.1.1.2. Regenerative Medicines Market: By Material, 2020-2030, USD (Billion)
9.5.1.1.3. Regenerative Medicines Market: By Application, 2020-2030, USD (Billion)
9.5.1.2. Japan
9.5.1.2.1. Regenerative Medicines Market: By Product, 2020-2030, USD (Billion)
9.5.1.2.2. Regenerative Medicines Market: By Material, 2020-2030, USD (Billion)
9.5.1.2.3. Regenerative Medicines Market: By Application, 2020-2030, USD (Billion)
9.5.1.3. India
9.5.1.3.1. Regenerative Medicines Market: By Product, 2020-2030, USD (Billion)
9.5.1.3.2. Regenerative Medicines Market: By Material, 2020-2030, USD (Billion)
9.5.1.3.3. Regenerative Medicines Market: By Application, 2020-2030, USD (Billion)
9.5.1.4. Australia
9.5.1.4.1. Regenerative Medicines Market: By Product, 2020-2030, USD (Billion)
9.5.1.4.2. Regenerative Medicines Market: By Material, 2020-2030, USD (Billion)
9.5.1.4.3. Regenerative Medicines Market: By Application, 2020-2030, USD (Billion)
9.5.1.5. South Korea
9.5.1.5.1. Regenerative Medicines Market: By Product, 2020-2030, USD (Billion)
9.5.1.5.2. Regenerative Medicines Market: By Material, 2020-2030, USD (Billion)
9.5.1.5.3. Regenerative Medicines Market: By Application, 2020-2030, USD (Billion)
9.5.1.6. Rest of Asia Pacific
9.5.1.6.1. Regenerative Medicines Market: By Product, 2020-2030, USD (Billion)
9.5.1.6.2. Regenerative Medicines Market: By Material, 2020-2030, USD (Billion)
9.5.1.6.3. Regenerative Medicines Market: By Application, 2020-2030, USD (Billion)
10. Latin America Regenerative Medicines Market, 2020-2030, USD (Billion)
10.1. Market Overview
10.2. Regenerative Medicines Market: By Product, 2020-2030, USD (Billion)
10.3. Regenerative Medicines Market: By Material, 2020-2030, USD (Billion)
10.4. Regenerative Medicines Market: By Application, 2020-2030, USD (Billion)
10.5.Regenerative Medicines Market: By Region, 2020-2030, USD (Billion)
10.5.1.Latin America
10.5.1.1. Brazil
10.5.1.1.1. Regenerative Medicines Market: By Product, 2020-2030, USD (Billion)
10.5.1.1.2. Regenerative Medicines Market: By Material, 2020-2030, USD (Billion)
10.5.1.1.3. Regenerative Medicines Market: By Application, 2020-2030, USD (Billion)
10.5.1.2. Mexico
10.5.1.2.1. Regenerative Medicines Market: By Product, 2020-2030, USD (Billion)
10.5.1.2.2. Regenerative Medicines Market: By Material, 2020-2030, USD (Billion)
10.5.1.2.3. Regenerative Medicines Market: By Application, 2020-2030, USD (Billion)
10.5.1.3. Rest of Latin America
10.5.1.3.1. Regenerative Medicines Market: By Product, 2020-2030, USD (Billion)
10.5.1.3.2. Regenerative Medicines Market: By Material, 2020-2030, USD (Billion)
10.5.1.3.3. Regenerative Medicines Market: By Application, 2020-2030, USD (Billion)
11. Middle East and Africa Regenerative Medicines Market, 2020-2030, USD (Billion)
11.1. Market Overview
11.2. Regenerative Medicines Market: By Product, 2020-2030, USD (Billion)
11.3. Regenerative Medicines Market: By Material, 2020-2030, USD (Billion)
11.4. Regenerative Medicines Market: By Application, 2020-2030, USD (Billion)
11.5.Regenerative Medicines Market: By Region, 2020-2030, USD (Billion)
11.5.1.Middle East and Africa
11.5.1.1. GCC
11.5.1.1.1. Regenerative Medicines Market: By Product, 2020-2030, USD (Billion)
11.5.1.1.2. Regenerative Medicines Market: By Material, 2020-2030, USD (Billion)
11.5.1.1.3. Regenerative Medicines Market: By Application, 2020-2030, USD (Billion)
11.5.1.2. Africa
11.5.1.2.1. Regenerative Medicines Market: By Product, 2020-2030, USD (Billion)
11.5.1.2.2. Regenerative Medicines Market: By Material, 2020-2030, USD (Billion)
11.5.1.2.3. Regenerative Medicines Market: By Application, 2020-2030, USD (Billion)
11.5.1.3. Rest of Middle East and Africa
11.5.1.3.1. Regenerative Medicines Market: By Product, 2020-2030, USD (Billion)
11.5.1.3.2. Regenerative Medicines Market: By Material, 2020-2030, USD (Billion)
11.5.1.3.3. Regenerative Medicines Market: By Application, 2020-2030, USD (Billion)
12. Company Profile
12.1. Medtronic plc
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. Zimmer Biomet Holdings, Inc.
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. Allergan plc
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. Athersys, Inc.
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. ACell, Inc.
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. Organogenesis Holdings Inc.
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. Tissue Regenix Group plc
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. Stryker Corporation
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. RTI Surgical, Inc.
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Integra LifeSciences Corporation
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives
12.11. ReproCell, Inc.
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Product Portfolio
12.11.4. Strategic Initiatives
12.12. Baxter International, Inc.
12.12.1. Company Overview
12.12.2. Financial Performance
12.12.3. Product Portfolio
12.12.4. Strategic Initiatives
List of Figures
Figure 1 Global Regenerative Medicines Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Regenerative Medicines Market: Quality Assurance
Figure 5 Global Regenerative Medicines Market, By Product, 2021
Figure 6 Global Regenerative Medicines Market, By Material, 2021
Figure 7 Global Regenerative Medicines Market, By Application, 2021
Figure 8 Global Regenerative Medicines Market, By Geography, 2021
Figure 9 Market Geographical Opportunity Matrix - Global Regenerative Medicines Market, 2021
Figure 10 Market Positioning of Key Regenerative Medicines Market Players, 2021
Figure 11 Global Regenerative Medicines Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 12 Porters Five Force Model - Current, Midterm and Long Term Perspective
Figure 13 See Saw Analysis
Figure 14 PETEL Analysis
Figure 15 Key Buying Criteria: Current and Long-Term Perspective
Figure 16 Global Regenerative Medicines Market, Scenario Analysis, 2020 to 2030 (US$ Billion)
Figure 17 Heptalysis Analysis: Global Regenerative Medicines Market
Figure 18 Five Whys Analysis
Figure 19 Global Regenerative Medicines Market, By Product, 2021 Vs 2030, %
Figure 20 Global Regenerative Medicines Market, By Material, 2021 Vs 2030, %
Figure 21 Global Regenerative Medicines Market, By Application, 2021 Vs 2030, %
Figure 22 U.S. Regenerative Medicines Market (US$ Billion), 2020 - 2030
Figure 23 Canada Regenerative Medicines Market (US$ Billion), 2020 - 2030
Figure 24 Rest of North America Regenerative Medicines Market (US$ Billion), 2020 - 2030
Figure 25 UK Regenerative Medicines Market (US$ Billion), 2020 - 2030
Figure 26 Germany Regenerative Medicines Market (US$ Billion), 2020 - 2030
Figure 27 Spain Regenerative Medicines Market (US$ Billion), 2020 - 2030
Figure 28 Italy Regenerative Medicines Market (US$ Billion), 2020 - 2030
Figure 29 France Regenerative Medicines Market (US$ Billion), 2020 - 2030
Figure 30 Rest of Europe Regenerative Medicines Market (US$ Billion), 2020 - 2030
Figure 31 China Regenerative Medicines Market (US$ Billion), 2020 - 2030
Figure 32 Japan Regenerative Medicines Market (US$ Billion), 2020 - 2030
Figure 33 India Regenerative Medicines Market (US$ Billion), 2020 - 2030
Figure 34 Australia Regenerative Medicines Market (US$ Billion), 2020 - 2030
Figure 35 South Korea Regenerative Medicines Market (US$ Billion), 2020 - 2030
Figure 36 Rest of Asia Regenerative Medicines Market (US$ Billion), 2020 - 2030
Figure 37 Brazil Regenerative Medicines Market (US$ Billion), 2020 - 2030
Figure 38 Mexico Regenerative Medicines Market (US$ Billion), 2020 - 2030
Figure 39 Rest of Latin America Regenerative Medicines Market (US$ Billion), 2020 - 2030
Figure 40 GCC Regenerative Medicines Market (US$ Billion), 2020 - 2030
Figure 41 Africa Regenerative Medicines Market (US$ Billion), 2020 - 2030
Figure 42 Rest of Middle East and Africa Regenerative Medicines Market (US$ Billion), 2020 - 2030
List of Tables
Table 1 Global Regenerative Medicines Market By Product, 2020-2030, USD (Billion)
Table 2 Global Regenerative Medicines Market By Material, 2020-2030, USD (Billion)
Table 3 Global Regenerative Medicines Market By Synthetic material, 2020-2030, USD (Billion)
Table 4 Global Regenerative Medicines Market By Biologically derived material, 2020-2030, USD (Billion)
Table 5 Global Regenerative Medicines Market By Genetically Engineered Material, 2020-2030, USD (Billion)
Table 6 Global Regenerative Medicines Market By Pharmaceutical, 2020-2030, USD (Billion)
Table 7 Global Regenerative Medicines Market By Application, 2020-2030, USD (Billion)
Table 8 North America Regenerative Medicines Market By Product, 2020-2030, USD (Billion)
Table 9 North America Regenerative Medicines Market By Material, 2020-2030, USD (Billion)
Table 10 North America Regenerative Medicines Market By Synthetic material, 2020-2030, USD (Billion)
Table 11 North America Regenerative Medicines Market By Biologically derived material, 2020-2030, USD (Billion)
Table 12 North America Regenerative Medicines Market By Genetically Engineered Material, 2020-2030, USD (Billion)
Table 13 North America Regenerative Medicines Market By Pharmaceutical, 2020-2030, USD (Billion)
Table 14 North America Regenerative Medicines Market By Application, 2020-2030, USD (Billion)
Table 15 U.S. Regenerative Medicines Market By Product, 2020-2030, USD (Billion)
Table 16 U.S. Regenerative Medicines Market By Material, 2020-2030, USD (Billion)
Table 17 U.S. Regenerative Medicines Market By Synthetic material, 2020-2030, USD (Billion)
Table 18 U.S. Regenerative Medicines Market By Biologically derived material, 2020-2030, USD (Billion)
Table 19 U.S. Regenerative Medicines Market By Genetically Engineered Material, 2020-2030, USD (Billion)
Table 20 U.S. Regenerative Medicines Market By Pharmaceutical, 2020-2030, USD (Billion)
Table 21 U.S. Regenerative Medicines Market By Application, 2020-2030, USD (Billion)
Table 22 Canada Regenerative Medicines Market By Product, 2020-2030, USD (Billion)
Table 23 Canada Regenerative Medicines Market By Material, 2020-2030, USD (Billion)
Table 24 Canada Regenerative Medicines Market By Synthetic material, 2020-2030, USD (Billion)
Table 25 Canada Regenerative Medicines Market By Biologically derived material, 2020-2030, USD (Billion)
Table 26 Canada Regenerative Medicines Market By Genetically Engineered Material, 2020-2030, USD (Billion)
Table 27 Canada Regenerative Medicines Market By Pharmaceutical, 2020-2030, USD (Billion)
Table 28 Canada Regenerative Medicines Market By Application, 2020-2030, USD (Billion)
Table 29 Rest of North America Regenerative Medicines Market By Product, 2020-2030, USD (Billion)
Table 30 Rest of North America Regenerative Medicines Market By Material, 2020-2030, USD (Billion)
Table 31 Rest of North America Regenerative Medicines Market By Synthetic material, 2020-2030, USD (Billion)
Table 32 Rest of North America Regenerative Medicines Market By Biologically derived material, 2020-2030, USD (Billion)
Table 33 Rest of North America Regenerative Medicines Market By Genetically Engineered Material, 2020-2030, USD (Billion)
Table 34 Rest of North America Regenerative Medicines Market By Pharmaceutical, 2020-2030, USD (Billion)
Table 35 Rest of North America Regenerative Medicines Market By Application, 2020-2030, USD (Billion)
Table 36 UK and European Union Regenerative Medicines Market By Product, 2020-2030, USD (Billion)
Table 37 UK and European Union Regenerative Medicines Market By Material, 2020-2030, USD (Billion)
Table 38 UK and European Union Regenerative Medicines Market By Synthetic material, 2020-2030, USD (Billion)
Table 39 UK and European Union Regenerative Medicines Market By Biologically derived material, 2020-2030, USD (Billion)
Table 40 UK and European Union Regenerative Medicines Market By Genetically Engineered Material, 2020-2030, USD (Billion)
Table 41 UK and European Union Regenerative Medicines Market By Pharmaceutical, 2020-2030, USD (Billion)
Table 42 UK and European Union Regenerative Medicines Market By Application, 2020-2030, USD (Billion)
Table 43 UK Regenerative Medicines Market By Product, 2020-2030, USD (Billion)
Table 44 UK Regenerative Medicines Market By Material, 2020-2030, USD (Billion)
Table 45 UK Regenerative Medicines Market By Synthetic material, 2020-2030, USD (Billion)
Table 46 UK Regenerative Medicines Market By Biologically derived material, 2020-2030, USD (Billion)
Table 47 UK Regenerative Medicines Market By Genetically Engineered Material, 2020-2030, USD (Billion)
Table 48 UK Regenerative Medicines Market By Pharmaceutical, 2020-2030, USD (Billion)
Table 49 UK Regenerative Medicines Market By Application, 2020-2030, USD (Billion)
Table 50 Germany Regenerative Medicines Market By Product, 2020-2030, USD (Billion)
Table 51 Germany Regenerative Medicines Market By Material, 2020-2030, USD (Billion)
Table 52 Germany Regenerative Medicines Market By Synthetic material, 2020-2030, USD (Billion)
Table 53 Germany Regenerative Medicines Market By Biologically derived material, 2020-2030, USD (Billion)
Table 54 Germany Regenerative Medicines Market By Genetically Engineered Material, 2020-2030, USD (Billion)
Table 55 Germany Regenerative Medicines Market By Pharmaceutical, 2020-2030, USD (Billion)
Table 56 Germany Regenerative Medicines Market By Application, 2020-2030, USD (Billion)
Table 57 Spain Regenerative Medicines Market By Product, 2020-2030, USD (Billion)
Table 58 Spain Regenerative Medicines Market By Material, 2020-2030, USD (Billion)
Table 59 Spain Regenerative Medicines Market By Synthetic material, 2020-2030, USD (Billion)
Table 60 Spain Regenerative Medicines Market By Biologically derived material, 2020-2030, USD (Billion)
Table 61 Spain Regenerative Medicines Market By Genetically Engineered Material, 2020-2030, USD (Billion)
Table 62 Spain Regenerative Medicines Market By Pharmaceutical, 2020-2030, USD (Billion)
Table 63 Spain Regenerative Medicines Market By Application, 2020-2030, USD (Billion)
Table 64 Italy Regenerative Medicines Market By Product, 2020-2030, USD (Billion)
Table 65 Italy Regenerative Medicines Market By Material, 2020-2030, USD (Billion)
Table 66 Italy Regenerative Medicines Market By Synthetic material, 2020-2030, USD (Billion)
Table 67 Italy Regenerative Medicines Market By Biologically derived material, 2020-2030, USD (Billion)
Table 68 Italy Regenerative Medicines Market By Genetically Engineered Material, 2020-2030, USD (Billion)
Table 69 Italy Regenerative Medicines Market By Pharmaceutical, 2020-2030, USD (Billion)
Table 70 Italy Regenerative Medicines Market By Application, 2020-2030, USD (Billion)
Table 71 France Regenerative Medicines Market By Product, 2020-2030, USD (Billion)
Table 72 France Regenerative Medicines Market By Material, 2020-2030, USD (Billion)
Table 73 France Regenerative Medicines Market By Synthetic material, 2020-2030, USD (Billion)
Table 74 France Regenerative Medicines Market By Biologically derived material, 2020-2030, USD (Billion)
Table 75 France Regenerative Medicines Market By Genetically Engineered Material, 2020-2030, USD (Billion)
Table 76 France Regenerative Medicines Market By Pharmaceutical, 2020-2030, USD (Billion)
Table 77 France Regenerative Medicines Market By Application, 2020-2030, USD (Billion)
Table 78 Rest of Europe Regenerative Medicines Market By Product, 2020-2030, USD (Billion)
Table 79 Rest of Europe Regenerative Medicines Market By Material, 2020-2030, USD (Billion)
Table 80 Rest of Europe Regenerative Medicines Market By Synthetic material, 2020-2030, USD (Billion)
Table 81 Rest of Europe Regenerative Medicines Market By Biologically derived material, 2020-2030, USD (Billion)
Table 82 Rest of Europe Regenerative Medicines Market By Genetically Engineered Material, 2020-2030, USD (Billion)
Table 83 Rest of Europe Regenerative Medicines Market By Pharmaceutical, 2020-2030, USD (Billion)
Table 84 Rest of Europe Regenerative Medicines Market By Application, 2020-2030, USD (Billion)
Table 85 Asia Regenerative Medicines Market By Product, 2020-2030, USD (Billion)
Table 86 Asia Regenerative Medicines Market By Material, 2020-2030, USD (Billion)
Table 87 Asia Regenerative Medicines Market By Synthetic material, 2020-2030, USD (Billion)
Table 88 Asia Regenerative Medicines Market By Biologically derived material, 2020-2030, USD (Billion)
Table 89 Asia Regenerative Medicines Market By Genetically Engineered Material, 2020-2030, USD (Billion)
Table 90 Asia Regenerative Medicines Market By Pharmaceutical, 2020-2030, USD (Billion)
Table 91 Asia Regenerative Medicines Market By Application, 2020-2030, USD (Billion)
Table 92 China Regenerative Medicines Market By Product, 2020-2030, USD (Billion)
Table 93 China Regenerative Medicines Market By Material, 2020-2030, USD (Billion)
Table 94 China Regenerative Medicines Market By Synthetic material, 2020-2030, USD (Billion)
Table 95 China Regenerative Medicines Market By Biologically derived material, 2020-2030, USD (Billion)
Table 96 China Regenerative Medicines Market By Genetically Engineered Material, 2020-2030, USD (Billion)
Table 97 China Regenerative Medicines Market By Pharmaceutical, 2020-2030, USD (Billion)
Table 98 China Regenerative Medicines Market By Application, 2020-2030, USD (Billion)
Table 99 Japan Regenerative Medicines Market By Product, 2020-2030, USD (Billion)
Table 100 Japan Regenerative Medicines Market By Material, 2020-2030, USD (Billion)
Table 101 Japan Regenerative Medicines Market By Synthetic material, 2020-2030, USD (Billion)
Table 102 Japan Regenerative Medicines Market By Biologically derived material, 2020-2030, USD (Billion)
Table 103 Japan Regenerative Medicines Market By Genetically Engineered Material, 2020-2030, USD (Billion)
Table 104 Japan Regenerative Medicines Market By Pharmaceutical, 2020-2030, USD (Billion)
Table 105 Japan Regenerative Medicines Market By Application, 2020-2030, USD (Billion)
Table 106 India Regenerative Medicines Market By Product, 2020-2030, USD (Billion)
Table 107 India Regenerative Medicines Market By Material, 2020-2030, USD (Billion)
Table 108 India Regenerative Medicines Market By Synthetic material, 2020-2030, USD (Billion)
Table 109 India Regenerative Medicines Market By Biologically derived material, 2020-2030, USD (Billion)
Table 110 India Regenerative Medicines Market By Genetically Engineered Material, 2020-2030, USD (Billion)
Table 111 India Regenerative Medicines Market By Pharmaceutical, 2020-2030, USD (Billion)
Table 112 India Regenerative Medicines Market By Application, 2020-2030, USD (Billion)
Table 113 Australia Regenerative Medicines Market By Product, 2020-2030, USD (Billion)
Table 114 Australia Regenerative Medicines Market By Material, 2020-2030, USD (Billion)
Table 115 Australia Regenerative Medicines Market By Synthetic material, 2020-2030, USD (Billion)
Table 116 Australia Regenerative Medicines Market By Biologically derived material, 2020-2030, USD (Billion)
Table 117 Australia Regenerative Medicines Market By Genetically Engineered Material, 2020-2030, USD (Billion)
Table 118 Australia Regenerative Medicines Market By Pharmaceutical, 2020-2030, USD (Billion)
Table 119 Australia Regenerative Medicines Market By Application, 2020-2030, USD (Billion)
Table 120 South Korea Regenerative Medicines Market By Product, 2020-2030, USD (Billion)
Table 121 South Korea Regenerative Medicines Market By Material, 2020-2030, USD (Billion)
Table 122 South Korea Regenerative Medicines Market By Synthetic material, 2020-2030, USD (Billion)
Table 123 South Korea Regenerative Medicines Market By Biologically derived material, 2020-2030, USD (Billion)
Table 124 South Korea Regenerative Medicines Market By Genetically Engineered Material, 2020-2030, USD (Billion)
Table 125 South Korea Regenerative Medicines Market By Pharmaceutical, 2020-2030, USD (Billion)
Table 126 South Korea Regenerative Medicines Market By Application, 2020-2030, USD (Billion)
Table 127 Latin America Regenerative Medicines Market By Product, 2020-2030, USD (Billion)
Table 128 Latin America Regenerative Medicines Market By Material, 2020-2030, USD (Billion)
Table 129 Latin America Regenerative Medicines Market By Synthetic material, 2020-2030, USD (Billion)
Table 130 Latin America Regenerative Medicines Market By Biologically derived material, 2020-2030, USD (Billion)
Table 131 Latin America Regenerative Medicines Market By Genetically Engineered Material, 2020-2030, USD (Billion)
Table 132 Latin America Regenerative Medicines Market By Pharmaceutical, 2020-2030, USD (Billion)
Table 133 Latin America Regenerative Medicines Market By Application, 2020-2030, USD (Billion)
Table 134 Brazil Regenerative Medicines Market By Product, 2020-2030, USD (Billion)
Table 135 Brazil Regenerative Medicines Market By Material, 2020-2030, USD (Billion)
Table 136 Brazil Regenerative Medicines Market By Synthetic material, 2020-2030, USD (Billion)
Table 137 Brazil Regenerative Medicines Market By Biologically derived material, 2020-2030, USD (Billion)
Table 138 Brazil Regenerative Medicines Market By Genetically Engineered Material, 2020-2030, USD (Billion)
Table 139 Brazil Regenerative Medicines Market By Pharmaceutical, 2020-2030, USD (Billion)
Table 140 Brazil Regenerative Medicines Market By Application, 2020-2030, USD (Billion)
Table 141 Mexico Regenerative Medicines Market By Product, 2020-2030, USD (Billion)
Table 142 Mexico Regenerative Medicines Market By Material, 2020-2030, USD (Billion)
Table 143 Mexico Regenerative Medicines Market By Synthetic material, 2020-2030, USD (Billion)
Table 144 Mexico Regenerative Medicines Market By Biologically derived material, 2020-2030, USD (Billion)
Table 145 Mexico Regenerative Medicines Market By Genetically Engineered Material, 2020-2030, USD (Billion)
Table 146 Mexico Regenerative Medicines Market By Pharmaceutical, 2020-2030, USD (Billion)
Table 147 Mexico Regenerative Medicines Market By Application, 2020-2030, USD (Billion)
Table 148 Rest of Latin America Regenerative Medicines Market By Product, 2020-2030, USD (Billion)
Table 149 Rest of Latin America Regenerative Medicines Market By Material, 2020-2030, USD (Billion)
Table 150 Rest of Latin America Regenerative Medicines Market By Synthetic material, 2020-2030, USD (Billion)
Table 151 Rest of Latin America Regenerative Medicines Market By Biologically derived material, 2020-2030, USD (Billion)
Table 152 Rest of Latin America Regenerative Medicines Market By Genetically Engineered Material, 2020-2030, USD (Billion)
Table 153 Rest of Latin America Regenerative Medicines Market By Pharmaceutical, 2020-2030, USD (Billion)
Table 154 Rest of Latin America Regenerative Medicines Market By Application, 2020-2030, USD (Billion)
Table 155 Middle East and Africa Regenerative Medicines Market By Product, 2020-2030, USD (Billion)
Table 156 Middle East and Africa Regenerative Medicines Market By Material, 2020-2030, USD (Billion)
Table 157 Middle East and Africa Regenerative Medicines Market By Synthetic material, 2020-2030, USD (Billion)
Table 158 Middle East and Africa Regenerative Medicines Market By Biologically derived material, 2020-2030, USD (Billion)
Table 159 Middle East and Africa Regenerative Medicines Market By Genetically Engineered Material, 2020-2030, USD (Billion)
Table 160 Middle East and Africa Regenerative Medicines Market By Pharmaceutical, 2020-2030, USD (Billion)
Table 161 Middle East and Africa Regenerative Medicines Market By Application, 2020-2030, USD (Billion)
Table 162 GCC Regenerative Medicines Market By Product, 2020-2030, USD (Billion)
Table 163 GCC Regenerative Medicines Market By Material, 2020-2030, USD (Billion)
Table 164 GCC Regenerative Medicines Market By Synthetic material, 2020-2030, USD (Billion)
Table 165 GCC Regenerative Medicines Market By Biologically derived material, 2020-2030, USD (Billion)
Table 166 GCC Regenerative Medicines Market By Genetically Engineered Material, 2020-2030, USD (Billion)
Table 167 GCC Regenerative Medicines Market By Pharmaceutical, 2020-2030, USD (Billion)
Table 168 GCC Regenerative Medicines Market By Application, 2020-2030, USD (Billion)
Table 169 Africa Regenerative Medicines Market By Product, 2020-2030, USD (Billion)
Table 170 Africa Regenerative Medicines Market By Material, 2020-2030, USD (Billion)
Table 171 Africa Regenerative Medicines Market By Synthetic material, 2020-2030, USD (Billion)
Table 172 Africa Regenerative Medicines Market By Biologically derived material, 2020-2030, USD (Billion)
Table 173 Africa Regenerative Medicines Market By Genetically Engineered Material, 2020-2030, USD (Billion)
Table 174 Africa Regenerative Medicines Market By Pharmaceutical, 2020-2030, USD (Billion)
Table 175 Africa Regenerative Medicines Market By Application, 2020-2030, USD (Billion)
Table 176 Rest of Middle East and Africa Regenerative Medicines Market By Product, 2020-2030, USD (Billion)
Table 177 Rest of Middle East and Africa Regenerative Medicines Market By Material, 2020-2030, USD (Billion)
Table 178 Rest of Middle East and Africa Regenerative Medicines Market By Synthetic material, 2020-2030, USD (Billion)
Table 179 Rest of Middle East and Africa Regenerative Medicines Market By Biologically derived material, 2020-2030, USD (Billion)
Table 180 Rest of Middle East and Africa Regenerative Medicines Market By Genetically Engineered Material, 2020-2030, USD (Billion)
Table 181 Rest of Middle East and Africa Regenerative Medicines Market By Pharmaceutical, 2020-2030, USD (Billion)
Table 182 Rest of Middle East and Africa Regenerative Medicines Market By Application, 2020-2030, USD (Billion)

Companies Mentioned

  • Medtronic plc
  • Zimmer Biomet Holdings Inc.
  • Allergan plc
  • Athersys Inc.
  • ACell Inc.
  • Organogenesis Holdings Inc.
  • Tissue Regenix Group plc
  • Stryker Corporation
  • RTI Surgical Inc.
  • Integra LifeSciences Corporation
  • ReproCell Inc.
  • Baxter International Inc.